COMMUNIQUÉS West-GlobeNewswire

Gain Therapeutics CEO Gene Mack Issues Letter to Shareholders and Provides Operational Update
16/07/2026
BETHESDA, Md., July 16, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of [...]
Dyadic Expands Bio industrial Pipeline with New Proprietary Industrial Enzyme Program
16/07/2026
New initiative builds on EN3ZYME™ launch and highlights scalability of the Dapibus™ platform JUPITER, Fla., July 16, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (Nasdaq: DYAI) ("Dyadic" or the "Company"), d/b/a [...]
Better Blend to open two new Cincinnati-area locations
16/07/2026
New Hyde Park and Kenwood locations strengthen Greater Cincinnati presence CINCINNATI, July 16, 2026 (GLOBE NEWSWIRE) -- Better Blend, the Northern Kentucky-founded smoothie and wellness brand, is continuing its rapid [...]
Marius Pharmaceuticals Welcomes Department of Defense's New Testosterone Screening Initiative for U.S. Service Members
16/07/2026
RALEIGH, N.C., July 16, 2026 (GLOBE NEWSWIRE) -- Marius Pharmaceuticals, Inc. , a specialty pharmaceutical company advancing the science of testosterone therapy and hormone health, today welcomed Defense Secretary Pete [...]
CDT Equity Inc. Announces Reverse Stock Split
16/07/2026
NAPLES, Fla. and CAMBRIDGE, United Kingdom, July 16, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”), announces that its board of directors has approved a 1-for-10 reverse stock split of [...]
Rinascera Therapeutics Launches with Clinical-Stage Pipeline to Transform the Treatment of Genetic Skin Diseases
16/07/2026
- Initial financing led by Double Point Ventures with participation from Olive Tree Capital, Civilization Ventures and Toba Capital - - Supports advancement of RIN-001 for Gorlin Syndrome and RIN-002 for Dystrophic [...]
RapidPulse Secures Oversubscribed $48M Series B Financing to Advance Clinical Development of Next-Generation Stroke Aspiration Technology
16/07/2026
Round includes participation from Medtronic and top healthcare investors MIAMI, July 16, 2026 (GLOBE NEWSWIRE) -- RapidPulse, Inc., a medical technology company developing next-generation aspiration technology for the [...]
New Review Examines Anatomical and Methodological Differences Between Auricular and Cervical Vagus Nerve Stimulation
16/07/2026
ROCKAWAY, N.J., July 16, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company and leader in non-invasive vagus nerve stimulation technologies, today [...]
Umoja Biopharma Announces FDA Clearance of IND Application for UB-VV400, the Industry’s First Known CD22-Directed In Vivo CAR T Cell Therapy for Relapsed/Refractory B Cell Malignancies
16/07/2026
The company’s lead internal program expands its in vivo CAR T clinical pipeline for patients with relapsed/refractory B cell malignancies First patient expected to be dosed in Q3 2026 SEATTLE, July 16, 2026 (GLOBE [...]
Relmada Therapeutics to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026
16/07/2026
CORAL GABLES, Fla., July 16, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central [...]
Clearmind Medicine Reports Positive Retention Results for Intranasal Formulation of its Psychedelic-Based Neuroplastogen MEAI
16/07/2026
Vancouver, Canada, July 16, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), a clinical-stage biotechnology company pioneering non‑hallucinogenic neuroplastogen‑derived treatments for Alcohol Use [...]
BienRaíz Launches 240 mg Magnesium Glycinate Supplement, Expanding Its Daily Wellness Portfolio with Targeted Mineral Support
16/07/2026
NEW YORK, July 16, 2026 (GLOBE NEWSWIRE) -- BienRaíz today announced the launch of BienRaíz Magnesium Glycinate Supplement, a daily magnesium glycinate supplement formulated with 240 mg elemental magnesium per serving. [...]
Immuron FY26 Sales - Four Consecutive Quarters of Growth over Prior Year
16/07/2026
Sales Highlights (unaudited): Global FY26 sales AUD$7.7 million up 6% on prior comparative period (pcp) 2H FY26 sales AUD$3.5 million up 7% on pcp 4Q FY26 sales AUD$2.0 million up 2% on pcp Australia FY26 sales AUD$5.8 [...]
Zymeworks to Report Second Quarter 2026 Financial Results on August 6, 2026
16/07/2026
VANCOUVER, British Columbia, July 16, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, [...]
Diagonal Therapeutics Announces First Patient Dosed in Phase 1/2 DIAMOND Clinical Trial of DIAG723 for Hereditary Hemorrhagic Telangiectasia (HHT)
16/07/2026
First-in-class clustering agonist antibody DIAG723 is designed to restore ALK1 signaling, the genetically disrupted pathway that causes abnormal vascular development, bleeding, and arteriovenous malformations (AVMs) in [...]
4TEEN4 Receives U.S. FDA Fast Track Designation for Invobenitug in Cardiogenic Shock
16/07/2026
Hennigsdorf/Berlin, July 16, 2026 – 4TEEN4 Pharmaceuticals GmbH today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to invobenitug (formerly known as procizumab), for the [...]
Arletta Pharma Solutions Receives FDA Response Supporting the Clinical Development Program of Lybrido™ for Female Sexual Interest/Arousal Disorder in the US
16/07/2026
www.arlettapharmasolutions.com FDA endorses key elements of the proposed Phase 2 dose-ranging study and openness to a single pivotal Phase 3 study to support a future NDA Amsterdam, the Netherlands, 16 July 2026 — [...]
Angelini Pharma Completes Acquisition of Catalyst Pharmaceuticals
16/07/2026
The Italian pharma company grows its presence in the U.S. market and strengthens its global leadership in Brain Health and Rare Diseases Completion of the transaction gives Angelini Pharma ownership of Catalyst’s [...]
Pharming Group to report second quarter and first half 2026 financial results and provide business update on July 30
16/07/2026
Leiden, the Netherlands, July 16, 2026: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms that it will report its preliminary (unaudited) financial results for the second quarter and [...]

Pages